Monday 22 July 2019 ,
Monday 22 July 2019 ,
Latest News
  • Roads in flood-hit areas to be repaired before Eid: Quader
  • Rohingya Crisis: Dhaka seeks NAM, ASEAN member states' role
  • Lightning strikes kill 32 in India
  • DU students lock academic, admin buildings for 2nd day
  • Floods to prolong as more rainfalls likely
10 September, 2018 00:00 00 AM / LAST MODIFIED: 10 September, 2018 01:15:26 AM

FDA approves Xerava

drugs.com
FDA approves Xerava

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, recently announced that the U.S. Food and Drug Administration (FDA) has granted approval of Xerava (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI). In clinical trials, Xerava was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem.

Xerava is indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Xerava and other antibacterial drugs, Xerava should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

“The approval of Xerava is an extraordinary achievement, one for which we thank the patients who have participated in our clinical studies, study investigators and physicians as well as our dedicated employees,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase. “We are thrilled to have received FDA approval, and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe all within the same quarter. Each milestone is a significant accomplishment on its own and achieving both underscores the potential for Tetraphase and the medical need for Xerava.”

Dr. Barie added, “Eravacycline also has a favorable safety profile as observed in clinical trials, and no dose adjustment is required when given to patients with renal impairment, which is advantageous for seriously ill patients who may have impaired kidney function. Additionally, the drug may be given safely to patients who are allergic to penicillin. This new and novel treatment may be of great benefit to patients with complicated intra-abdominal infections.”

Intra-abdominal infection (IAI) is a common problem in clinical practice and comprises a wide variety of disease processes. IAI is classified as uncomplicated or complicated based on the extent of the infection. Complicated intra-abdominal infections (cIAI) extend beyond the source organ into the peritoneal space (the space between the two membranes that separate the organs in the abdominal cavity from the abdominal wall) as a result of perforation or other damage to the gastrointestinal tract. cIAI diagnoses include intra-abdominal abscess, stomach or intestinal perforation, peritonitis, appendicitis, cholecystitis, or diverticulitis. Different bacterial pathogens are responsible for cIAI, including Gram-negative aerobic bacteria, Gram-positive bacteria, and anaerobic bacteria.

Early detection, containment and appropriate antimicrobial treatment are essential to the successful treatment of IAI. This is even more critical with increasing rates of infections caused by drug-resistant bacteria, which limit the effectiveness of currently available antibiotics.

Important safety information

Xerava is a tetracycline class antibacterial indicated for the treatment of complicated intra abdominal infections in patients 18 years of age and older.

Xerava is not indicated for the treatment of complicated urinary tract infections.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Xerava and other antibacterial drugs, Xerava should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Xerava is contraindicated for use in patients with known hypersensitivity to eravacycline or to tetracycline-class antibacterial drugs. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with Xerava.

The use of Xerava during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.

The use of Xerava during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.

The most common adverse reactions observed in clinical trials (incidence ≥ 3%) were infusion site reactions, nausea, and vomiting.

Xerava is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri, and anti anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with Xerava. Discontinue Xerava if any of these adverse reactions are suspected.

About Xerava

Xerava (eravacycline for injection) is a novel, fully-synthetic fluorocycline, FDA-approved antibiotic for the treatment of cIAI. Xerava has demonstrated potent activity against MDR pathogens.

Xerava was investigated for the treatment of cIAI as part of the Company's IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) phase 3 programs. In the first pivotal phase 3 trial in patients with cIAI, twice-daily intravenous (IV) eravacycline met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well-tolerated. In the second phase 3 clinical trial in patients with cIAI, twice-daily IV eravacycline met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well-tolerated. In both trials, Xerava achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates.

 

 

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

Dengue is creating a have in Bangladesh. This year in the capital till now 4549 people admitted in the hospital suffering from this disease. Recently…
Dengue --- a bird's eye view

Dengue --- a bird's eye view

Introduction Dengue (pronounced as Dengee) is a Spanish word. It probably originated fro the word Dinga in the Swahili phrase Ka-dinga pepo means disease…
Dengue and severe dengue

Dengue and severe dengue

Key facts • Dengue is a mosquito-borne viral infection. •    The infection causes flu-like illness, and occasionally develops…
Dengue

Dengue

How Dengue shock occur? Macrophage and monocyte infection by the Dengue virus sets off a chain of reactions causing release of cytokines and vaso active…
Children over six may be at greater risk of dengue infection

Children over six may be at greater risk of dengue infection

A new study with icddr,b identifies various household and community level risk factors that increase the risk of Dengue fever virus (DENV) infection.…
Phototherapy for psoriasis

Phototherapy for psoriasis

RUTH JESSEN HICKMAN, MD Phototherapy, also known as UV light therapy, is one of the most effective treatments for psoriasis. It involves exposing the…
3 Habits that can sabotage your metabolism

3 Habits that can sabotage your metabolism

When we’re having trouble losing weight, it can be tempting to place the blame entirely on our metabolism. Yes, metabolism matters, but it’s…
Researchers tie metabolic enzyme to obesity and fatty liver disease

Researchers tie metabolic enzyme to obesity and fatty liver disease

CHRIS WORTHY Researchers from Clemson University's Environmental Toxicology Program have published research connecting an enzyme associated with detoxification…
Are sugary drinks causing cancer?

Are sugary drinks causing cancer?

JAMES GALLAGHER  Sugary drinks - including fruit juice and fizzy pop - may increase the risk of cancer, French scientists say. The link was suggested…
icddr,b extends its laboratories service operation to 24 hours a day

icddr,b extends its laboratories service operation to 24 hours a day

Starting from 15 July 2019, icddr,b’s globally recognised diagnostic centre at Mohakhali, Dhaka is now operating its services 24 hours a day, 7…
Climate change cause health risk for children

Climate change cause health risk for children

Negative effects of climate change have resulted in health risk of our children. The government should take necessary steps for saving the future generation,…
DR Congo Ebola outbreak declared global health emergency

DR Congo Ebola outbreak declared global health emergency

The World Health Organization has declared the Ebola crisis in the Democratic Republic of Congo a "public health emergency of international concern".…
Safety practice violations ID'd in septic arthritis outbreak

Safety practice violations ID'd in septic arthritis outbreak

Breaches of recommended infection prevention practices have been identified in an outbreak of septic arthritis cases after intra-articular injections…
FDA approves Xembify (immune globulin subcutaneous) for primary immunodeficiencies

FDA approves Xembify (immune globulin subcutaneous) for primary immunodeficiencies

Grifols, a leading global producer of plasma-derived medicines, announced recently that Xembify, its new 20% subcutaneous immunoglobulin, has been approved…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting